Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Professionals LLC

Neither a doctor nor a teaching hospital

Research payments

$36,095,233

501 payments

Through program year 2025, Clinical Research Professionals LLC is reported as receiving $36,095,233 in research payments, across 501 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,236,250 67
2024 Research $1,492,391 78
2023 Research $6,241,318 110
2022 Research $9,629,897 86
2021 Research $10,524,719 106
2020 Research $5,188,267 33
2019 Research $782,391 21

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $30,482,505 346 payments
  2. Eli Lilly and Company $5,484,954 90 payments
  3. Braintree Laboratories, Inc. $51,606 33 payments
  4. AbbVie, Inc. $26,362 15 payments
  5. GlaxoSmithKline, LLC. $22,739 10 payments
  6. Allergan Inc. $18,568 6 payments
  7. Gilead Sciences, Inc. $8,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $14,841,135 99 payments
  2. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $7,048,548 49 payments
  3. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $3,192,245 42 payments
  4. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $2,469,958 51 payments
  5. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,217,373 9 payments
  6. A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $940,531 28 payments
  7. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $842,708 4 payments
  8. A Phase 12 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $594,210 19 payments
  9. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $417,310 6 payments
  10. A Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccines Against Influenza in Healthy Adults $409,934 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record